Abstract
PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have